临床外科杂志 ›› 2025, Vol. 33 ›› Issue (10): 1073-1076.doi: 10.3969/j.issn.1005-6483.20241342

• 论著 • 上一篇    下一篇

术前经肝动脉化疗栓塞术对Ⅰb~Ⅱa期肝癌早期复发的影响

占学志 余金 朱媛 廖晓锋 李晓刚   

  1. 430065 湖北武汉,武汉科技大学医学部医学院(占学志,余金,朱媛);湖北文理学院附属襄阳市中心医院普外科(占学志,余金,朱媛,廖晓锋,李晓刚)
  • 收稿日期:2024-08-12 出版日期:2025-11-11 发布日期:2025-11-11
  • 通讯作者: 李晓刚,Email:wdxg@163.com

The influence of preoperative transarterial chemoembolizationon the early recurrence of stage Ⅰb-Ⅱa diagnosed liver cancer

ZHAN Xuezhi*,YU Jin,ZHU Yuan,LIAO Xiaofeng,LI Xiaogang   

  1. *School of Medicine,Wuhan University of Science and Technology,Wuhan 430065,China
  • Received:2024-08-12 Online:2025-11-11 Published:2025-11-11

摘要: 目的 探讨术前经肝动脉化疗栓塞术(TACE)对中国肝癌分期(CNLC)Ⅰb-Ⅱa期病人术后早期复发的影响。方法 2017年5月~2022年5月诊断为CNLC Ⅰb-Ⅱa期肝细胞癌并行根治性切除病人76例,依据术前是否行TACE分为两组,其中术前TACE组32例,直接手术组44例。观察病人术后恢复情况,结合术后病理结果,行辅助TACE治疗,出院后定期复查随访。采用Kaplan-Meier法对生存时间进行估计并计算95%CI,使用Kaplan-Meier法绘制无病生存曲线,使用Cox比例风险模型进行单因素及多因素分析。结果 术前TACE组术后1年无病生存率高于直接手术组(96.9%比84.1%,P>0.05),术前TACE组术后2年无病生存率高于直接手术组(90.6%比70.5%,P<0.05),术前TACE组无病生存期高于直接手术组(23.03个月比20.14个月,P<0.05),术前TACE组手术后治疗相关不良事件高于直接手术组(34.4%比20.5%,P>0.05),差异均有统计学意义。多因素Cox回归分析表明,不同治疗方式、肿瘤数≥2枚、肿瘤微血管侵犯为影响肿瘤复发的独立预后危险因素。两组未发生严重不良反应,均未观察到不良反应所致的死亡。结论 与直接手术相比,术前TACE有助于改善术后早期复发,延长病人无病生存期,且不会导致严重不良事件的发生。

关键词: 肝细胞癌, 经肝动脉化疗栓塞术, 术前治疗, 早期复发

Abstract: Objective To explore the effects of preoperative transcatheter arterial chemoembolization (TACE) on early postoperative recurrence in the China liver cancer (CNLC) staging Ⅰb-Ⅱa patients with primary hepatocellular carcinoma.Methods The data of patients with CNLC Ⅰb-Ⅱa stage hepatocellular carcinoma who underwent curative liver resection in Xiangyang Central Hospital from May 2017 to May 2022 were retrospectively analyzed.A total of 76 patients were included,patients were divided into preoperative TACE group (n=32) and surgery group (n=44) according to whether they underwent preoperative TACE.Observe the postoperative recovery of patients.Combined with the postoperative pathological results,adjuvant TACE treatment is performed.Regular reexamination and follow-up are conducted after discharge.The Kaplan-Meier method was used to estimate survival time,calculate 95%CI,and plot the Disease-free (DFS) survival curve.The Cox proportional risk model was used for univariate and multivariate analysis.Results The 1-year disease-free survival rate in the preoperative TACE group was higher than that in the direct surgery group (96.9% vs. 84.1%,P>0.05).The 2-year disease-free survival rate in the preoperative TACE group was higher than that in the direct surgery group (90.6% vs. 70.5%,P<0.05).The disease-free survival of the preoperative TACE group was higher than the direct surgery group (23.03 months vs. 20.14 months,P<0.05).The incidence of treatment-related adverse events after surgery in the preoperative TACE group was higher than that in the direct surgery group (34.4% vs. 20.5%,P>0.05).Multivariate Cox regression analysis showed that different treatment methods,tumor number ≥ 2,and tumor microvascular invasion were prognostic factors affecting tumor recurrence.No severe adverse reactions occurred in either group,and no deaths caused by adverse reactions were observed.

Key words: hepatocellular carcinoma, transarterial chemoembolization, preoperative therapy, early recurrence

[1] 潘均昊, 王春晖. 基于SEER数据库构建远处转移性肝细胞癌的预后预测模型[J]. 临床外科杂志, 2025, 33(4): 410-415.
[2] 国际肝胆胰协会中国分会 中华医学会外科学分会肝脏外科学组. 肝细胞癌合并乙肝肝硬化病人肝切除安全性评估专家共识[J]. 临床外科杂志, 2025, 33(3): 225-236.
[3] 王豪 梁宾勇 梅斌. 以免疫检查点抑制剂为基础的肝细胞癌新辅助治疗进展[J]. 临床外科杂志, 2025, 33(3): 332-335.
[4] 郭昌德 夏锋. 系统联合局部治疗在不可切除肝细胞癌中的临床实践与展望[J]. 临床外科杂志, 2025, 33(10): 1039-1042.
[5] 杨鑫 许达 钦伦秀. 肝癌肝切除的现状和挑战[J]. 临床外科杂志, 2025, 33(10): 1048-1052.
[6] 唐浩文 曹银彪 卢实春. 肝细胞癌合并门静脉癌栓处理的新策略[J]. 临床外科杂志, 2025, 33(10): 1053-1057.
[7] 周一 梁宾勇 肖震宇. 免疫检查点抑制剂治疗晚期肝细胞癌的研究进展[J]. 临床外科杂志, 2024, 32(3): 328-331.
[8] 熊坚威 李强 唐涛 张立鑫 英保 赵开烽 熊永福 李敬东 武国. 经肝动脉化疗栓塞联合酪氨酸激酶抑制剂及程序性死亡受体-1抗体治疗中晚期不可切除肝细胞癌的临床疗效和安全性分析[J]. 临床外科杂志, 2024, 32(2): 176-181.
[9] 瞿伟峰 史颖弘 樊嘉. 美国国立综合癌症网络临床实践指南:肝细胞癌(2023.V2)更新解读[J]. 临床外科杂志, 2024, 32(1): 6-9.
[10] 慕喜喜 李静 张玄 高小鹏 刘保荣 钟岳. miR-3619-5p、LINC00857在原发性肝细胞癌血清中表达水平及其临床诊断价值分析[J]. 临床外科杂志, 2023, 31(6): 572-575.
[11] 刘金玮 巴林超 张劲夫 范正军. 低氧脂滴诱导相关蛋白在肝细胞癌中的表达情况及临床意义[J]. 临床外科杂志, 2023, 31(5): 447-452.
[12] 曾祥宇 王涛 蒋祈 杜雨强 杨文昶 沈乾 吕剑波 刘炜圳 陶凯雄 王国斌 张鹏. 中低位直肠胃肠间质瘤伊马替尼术前治疗的疗效分析[J]. 临床外科杂志, 2023, 31(3): 252-255.
[13] 熊坚威 武国 赵开烽 英保. 肝动脉化疗栓塞联合卡瑞利珠单抗成功转化不可切除肝癌一例[J]. 临床外科杂志, 2023, 31(2): 136-137.
[14] 林丽燕 董佳 肖伟进 彭然 吴方君 马辉 力超 刘景丰. 基于全偏振成像和机器学习的肝细胞癌与肝内胆管癌鉴别诊断研究[J]. 临床外科杂志, 2023, 31(2): 164-167.
[15] 武烨晔 王葵. 肝细胞癌的术后辅助治疗现状及展望[J]. 临床外科杂志, 2023, 31(10): 907-910.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!